Formycon Delay Pushes Back Coherus’ Ranibizumab
FDA Requests Additional Data On Lucentis Rival
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.
You may also be interested in...
A ruling by the High Court has cut almost two years from UK SPC protection for Roche's Lucentis ranibizumab brand, potentially offering biosimilar competitors the change to jump into the market early.
Coherus BioSciences sees value in having both wholly-owned and in-licensed biosimilar assets, as the firm gears up to have a portfolio of at least six products within five years.
The latest drug development news and highlights from our US FDA Performance Tracker.